Biografi
“Fokus saya selalu pada pasien, memberikan pengobatan holistik berdasarkan penelitian ilmiah yang tidak hanya menangani penyakit tetapi juga mendukung pasien dan keluarga mereka sepanjang perjalanan pengobatan. Saya sangat antusias dalam penelitian dan berkomitmen untuk memajukan masa depan pengobatan kelainan darah dan kanker.”
Dr. Tan Sui Keat menangani semua kondisi hematologi dan kanker darah dengan spesialisasi pada Leukemia, Limfoma, Multiple Myeloma, Transplantasi Sumsum Tulang, dan Terapi Seluler.
Dr. Tan menyelesaikan gelar Doctor of Medicine di Universiti Kebangsaan Malaysia (UKM) pada tahun 2008 dan 2015, serta meraih gelar Membership of the Royal Colleges of Physicians of the United Kingdom, MRCP (UK). Didorong oleh minatnya di bidang hematologi, ia kemudian melanjutkan pendidikan Fellowship di bidang Transplantasi Sumsum Tulang dan Sel Punca di St Vincent Hospital di Sydney, Australia, pada 2020.
Dengan pengalaman medis lebih dari 17 tahun dan spesialisasi di bidang hematologi selama 7 tahun, Dr. Tan menjadi seorang ahli hematologi yang sangat berpengalaman. Ia telah diundang untuk tampil di beberapa konferensi medis lokal dan regional yang bergengsi. Hingga saat ini, ia telah menyampaikan lebih dari 15 presentasi lisan dan poster, termasuk presentasi lisan yang penting tentang 'Genotype and Clinical Characterization of HbH Disease in Malaysian Patients' di British Society of Hematology Annual Congress di 2022, the Congress of the Asia Pacific Society on Thrombosis and Hemostasis dan the 28th Annual Meeting of the Asia-Pacific Blood and Marrow Transplantation Group di 2023.
Ia telah memberikan kontribusi signifikan kepada komunitas medis, dengan publikasi-publikasi penting seperti makalah yang ditulis sebagai penulis utama, 'Genotype and Clinical Characterisation of HbH Disease in Malaysian Patients' yang diterbitkan di British Journal of Hematology (April 2022), dan 'Risk Factors and Outcomes of COVID-19 Infection in Hematological Patients: A Multicenter Retrospective Analysis in Malaysia' yang diterbitkan di Blood (2022) 140 (Suplemen 1): 13232-13233.
Dr. Tan sangat antusias dalam bidang penelitian dan telah menjabat sebagai Principal Investigator dan Co-Investigator untuk lebih dari 10 uji klinis yang berfokus pada kelainan darah dan kanker. Ia juga merupakan anggota Cellular Therapy Advisory Committee of Malaysian Society of Hematology serta anggota Expert Committee Health Technology Assessment for CART Cell for Relapsed Refractory Acute Lymphoblastic Leukemia oleh Ministry of Health pada tahun 2024.
Komitmen Dr. Tan terhadap perawatan yang berpusat pada pasien telah membuatnya meraih Excellent Service Award dari Penang State Health Department sebanyak dua kali, yaitu pada tahun 2013 dan 2023, yang mencerminkan dedikasinya dalam memberikan perawatan yang dipersonalisasi dan pengobatan berbasis penelitian ilmiah.
Dr. Tan fasih berbahasa Inggris, Bahasa Melayu, Bahasa Mandarin, Bahasa Hokkien, dan Bahasa Kanton, sehingga pasien dan keluarga mereka merasa nyaman berkomunikasi dalam bahasa pilihan mereka.
Riset
COMMODORE (2018) – A Randomised, Open Label Phase 3 study assessing the safety and tolerability of the oral FLT3 inhibitor Gliteritinib versus salvage chemotherapy in relapsed or refractory AML – Co-investigator
EXPLORER 4 (2018) – A Randomised, Open Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylatic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors – Co-investigator
BELIEVE (2018) – A Phase 3, double blind, randomized, placebo-controlled, multicentre study to determine the efficacy and safety of luspatercept plus Best Supportive Care versus placebo plus BSC in adults who require regular red blood cell transfusion due to Beta Thalassemia – Co-investigator
VIALE –T (2020) – A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitdine after ASCT in subjects with AML – Co-investigator
VEDO-3035 (2020) – A Randomized, Double Blind, Placebo – controlled, Multicenter Study to evaluate the efficacy and safety of Vedolizumab in the prophylaxis of Intestinal acute GVHD in subjects undergoing alloSCT – Co-investigator
ASSURE (2020) – A Phase II dose escalation study of cyclophosphamide in hematopoietic stem cell transplantation in severe systemic sclerosis patient unfit for standard dose of cyclophosphamide – Co-investigator
IMARA (2021) — A Phase 2, Randomized, Double Blind, Placebo controlled study to evaluate the safety, tolerability, PK and PD of IMR-687 in adult subjects with B-Thalassemia – Co-investigator
BO42162 (2021) – A Phase III, Randomized, Open Label Active Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab versus Eculizumab in adult and adolescent patients with PNH not previously treated with complement inhibitors – Co-investigator
CABL001J12301(2022) – A Phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected TKI in patients with newly diagnosed CML in CP – Co-investigator
CABL001A2302(2022) – A Phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with CML in CP previously treated with 2 or more TKI – Co-investigator
MANIFEST II (2023) – A Phase 3, Randomized, Double – Blind, Active Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment Naïve MF Patients – Principal Investigator
MajesTEC-9 (2023) – SA Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 prior lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide – Principal Investigator
BELLWAVE (2024) – A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Ibrutinib or Acalabrutinib) in Participants with Untreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma – Principal Investigator
GOLSEEK (2025) – A phase 3, Multicenter, Randomized, Double Blind, Placebo- controlled Study. Comparing the Efficacy and Safety of Golcadomide plus R-CHOP Chemotherapy vs Placebo plus RCHOP Chemotherapy in Participants with Previously Untreated High – risk Large B cell Lymphoma – Principal Investigator
Publikasi
Variable CD34+ recovery of cryopreserved allogenic HPC products: transplant implication during the COVID -19 pandemic – Co-author and Site Investigator, Blood advance: published 4/9/2021
Genotype and Clinical Characterisation of HbH disease in Malaysian Patients – First author, British Journal of Hematology: published 3/4/2022
Risk factors and outcome of COVID-19 infection in Hematological Patients: A Multicenter Retrospective Analysis in Malaysia, First author, Blood (2022) 140 (Supplement 1): 13232-13233
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy in Heavily Pretreated Chronic GVHD Patients with Steroid Failure – Co-author and Site Investigator, Transplantation and Cellular Therapy (2022) 1-9
Utility of Osteoporosis Medications in Palliative Care and Oncology – Co-author, pharmacological interventions for Osteoporosis (pp.103-118)